1,846 Shares in HCA Healthcare, Inc. $HCA Bought by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. bought a new position in shares of HCA Healthcare, Inc. (NYSE:HCA) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 1,846 shares of the company’s stock, valued at approximately $787,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in HCA. Clearstead Trust LLC raised its stake in HCA Healthcare by 311.8% during the second quarter. Clearstead Trust LLC now owns 70 shares of the company’s stock worth $27,000 after buying an additional 53 shares during the last quarter. Harbor Capital Advisors Inc. boosted its position in shares of HCA Healthcare by 82.9% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 75 shares of the company’s stock valued at $32,000 after purchasing an additional 34 shares in the last quarter. Twin Peaks Wealth Advisors LLC bought a new stake in HCA Healthcare in the second quarter worth approximately $40,000. Compound Global Advisors LLC bought a new position in shares of HCA Healthcare during the 3rd quarter worth approximately $44,000. Finally, True Wealth Design LLC lifted its position in shares of HCA Healthcare by 179.5% during the 3rd quarter. True Wealth Design LLC now owns 109 shares of the company’s stock valued at $47,000 after acquiring an additional 70 shares during the period. 62.73% of the stock is owned by institutional investors and hedge funds.

HCA Healthcare Stock Down 2.8%

Shares of NYSE HCA opened at $525.56 on Friday. The company has a market capitalization of $117.53 billion, a PE ratio of 18.52, a PEG ratio of 1.66 and a beta of 1.36. The stock’s 50 day moving average price is $492.87 and its 200-day moving average price is $458.92. HCA Healthcare, Inc. has a twelve month low of $295.00 and a twelve month high of $552.90.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings data on Tuesday, January 27th. The company reported $8.01 earnings per share for the quarter, topping the consensus estimate of $7.37 by $0.64. The business had revenue of $19.51 billion for the quarter, compared to analysts’ expectations of $19.67 billion. HCA Healthcare had a negative return on equity of 409.11% and a net margin of 8.97%.The business’s revenue was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $6.22 earnings per share. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. As a group, research analysts expect that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 17th will be paid a $0.78 dividend. The ex-dividend date is Tuesday, March 17th. This represents a $3.12 dividend on an annualized basis and a yield of 0.6%. This is a positive change from HCA Healthcare’s previous quarterly dividend of $0.72. HCA Healthcare’s dividend payout ratio (DPR) is presently 10.15%.

Wall Street Analyst Weigh In

HCA has been the subject of several research reports. Wells Fargo & Company raised their target price on HCA Healthcare from $452.00 to $481.00 and gave the company an “equal weight” rating in a research note on Friday, January 30th. Mizuho boosted their price objective on HCA Healthcare from $540.00 to $585.00 and gave the company an “outperform” rating in a report on Wednesday. Morgan Stanley downgraded shares of HCA Healthcare from an “equal weight” rating to an “underweight” rating and set a $425.00 price target for the company. in a research report on Monday, December 15th. TD Cowen reaffirmed a “buy” rating on shares of HCA Healthcare in a research note on Wednesday, January 28th. Finally, Argus upped their target price on shares of HCA Healthcare from $530.00 to $560.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Sixteen analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $534.50.

Insider Buying and Selling

In related news, SVP Jennifer Berres sold 8,020 shares of the business’s stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $514.58, for a total transaction of $4,126,931.60. Following the sale, the senior vice president directly owned 11,993 shares in the company, valued at approximately $6,171,357.94. The trade was a 40.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael S. Cuffe sold 1,500 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $498.09, for a total value of $747,135.00. Following the sale, the executive vice president owned 30,003 shares in the company, valued at approximately $14,944,194.27. This represents a 4.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 15,214 shares of company stock valued at $7,797,595 over the last three months. Insiders own 1.30% of the company’s stock.

HCA Healthcare Company Profile

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.